Breast Cancer Research

CORRECTION   Open Access

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

Samuel A. Jacobs[1*], André Robidoux[1,2], Jame Abraham[1,3], José Manuel Pérez-Garcia[4,5], Nicla La Verde[6,7], James M. Orcutt[1,8], Marina E. Cazzaniga[5,9], Fanny Piette[10], Silvia Antolín[11], Elena Aguirre[5], Javier Cortes[4,5], Antonio Llombart-Cussac[5], Serena Di Cosimo[5,12], Rim S. Kim[1], Huichen Feng[1], Corey Lipchik[1], Peter C. Lucas[1,13], Ashok Srinivasan[1], Ying Wang[1], Nan Song[1], Patrick G. Gavin[1], April D. Balousek[1], Soonmyung Paik[1,14], Carmen J. Allegra[15], Norman Wolmark[1,16] and Katherine L. Pogue-Geile[1]

Correction to: Breast Cancer Res
https://doi.org/10.1186/s13058-019-1196-y

After the publication [1] the authors report corrections for Table 3, for the headers of columns 5 and 7, which should read as follows: Column 5 Header: P-value for pCR, T vs Other Arms in HR$^+$, and Column 7 Header: P-value for pCR, T vs Other Arms in HR$^-$.

The correct version of the table can be found below:

Author details
[1]NSABP Foundation, Inc., Nova Tower 2, Two Allegheny Center – Ste 1200, Pittsburgh, PA 15212, USA. [2]Centre hospitalier de l'université de Montréal, Montréal, QC, Canada. [3]Cleveland Clinic, Cleveland, OH, USA. [4]QuironSalud Group, IOB Institute of Oncology, Barcelona, Madrid, Spain. [5]Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. [6]Present address: ASST Fatebenefratelli Sacco - PO Luigi Sacco, Milan, Italy. [7]ASST Fatebenefratelli Sacco - PO Fatebenefratelli, Milan, Italy. [8]Roper St. Francis Healthcare, Charleston, SC, USA. [9]Azienda Ospedaliera San Gerardo, Monza, Italy. [10]International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium. [11]Hospital Universitario, Coruña, Spain. [12]Fondazione IRCCS Istituto Nazionale di Tumori, Milan, Italy. [13]Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. [14]Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of South Korea. [15]Department of Medicine, University of Florida Health, Gainsville, FL, USA. [16]University of Pittsburgh, Pittsburgh, PA 15212, USA.

Reference
1.   Jacobs, et al. Breast Cancer Res. 2019;21:133. https://doi.org/10.1186/s13058-019-1196-y.

The original article can be found online at https://doi.org/10.1186/s13058-019-1196-y

* Correspondence: samuel.jacobs@nsabp.org
[1]NSABP Foundation, Inc., Nova Tower 2, Two Allegheny Center – Ste 1200, Pittsburgh, PA 15212, USA
Full list of author information is available at the end of the article

Jacobs *et al. Breast Cancer Research*   (2020) 22:9

Page 2 of 2

Table 3 NSABP FB-7: Pathologic complete response (pCR) (breast and nodes) by treatment arm and HR status

Treatment arms, $n = 42$ each arm	Total pCR	*P-value* for pCR T vs Other Arms in all patients[a]	pCR HR$^+$	*P-value* for pCR T vs Other Arms in HR$^+$ [b]	pCR HR$^-$	*P-value* for pCR T vs Other Arms in HR$^-$ [b]	*P-value* HR$^+$ vs HR$^-$
Arm 1 (T)	16/41 (39.0%)	NA	8/27 (29.6%)	NA	8/14 (57.1%)	NA	0.11
Arm 2 (N)	14/42 (33.3%)	0.63	8/29 (27.6%)	1	6/13 (46.2%)	0.71	0.30
Arm 3 (T plus N)	21/42 (50%)	0.22	7/23 (30.4%)	1	14/19 (73.7%)	0.46	0.01
All arms	51/126 (40%)		23/79 (29%)		28/46 (61%)		0.001

Abbreviations: T, trastuzumab; N, neratinib
[a]CMH test stratified for the time period the patients were randomized to the study (prior/after the addition of Arm 3)
[b]Fisher's exact test